When was Valneva founded?

Valneva was founded in 1999 and raised its 1st funding round 9 years after it was founded.

Where is Valneva located?

Valneva is headquartered in Lyon, France.

How many employees does Valneva have?

As of Sep 30, 2026, the latest employee count at Valneva is 612.

Is Valneva a funded company?

Valneva is a funded company, having raised a total of $114M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 17, 2008.

When was the latest funding round of Valneva?

Valneva's latest funding was a $***** Post IPO round on Oct 05, 2022, with participation from 2 investors.

Where does Valneva rank among its competitors?

Valneva ranks 34th amongst 2754 active competitors, of which 910 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Valneva?

Valneva's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Valneva - 2026 Company Profile, Funding & Competitors

Company Details

Developer of prophylactic vaccines for infectious diseases. The company's lead candidate is VLA1553 is a live-attenuated, single dose vaccine targeting the chikungunya virus. Other products includes VLA15 for Lyme Disease, VLA84 for Clostridium difficile, and VLA1601 for zika virus

Website: valneva.com
Social

Key Metrics

Founded Year

1999

Location

Lyon, France

Stage

Public

Total Funding

$114M in 13 rounds

Latest Funding Round

Post IPO, Oct 05, 2022, $*****

Investors

Phase4 Partners & 14 more

Ranked

34^th among 2754 active competitors

Employee Count

612 as on Sep 30, 2026

Similar Companies

Moderna & 456 more

Exit Details

Public

View Valneva's full profile

Valneva got listed on Jun 01, 2007.

Click here to take a look at Valneva's IPO in detail

Valneva has raised a total funding of $114M over 13 rounds. Its first funding round was on Mar 17, 2008. Its latest funding round was a Post IPO round on Oct 05, 2022 for $*****. 2 investors participated in its latest round. Valneva has 15 institutional investors.

Here is the list of recent funding rounds of Valneva:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 05, 2022	5242044	Post IPO	5235744	8605195	6261266	4217570
Jun 20, 2022	6819125	Post IPO	4106729	9703141	1402116	Pfizer
Feb 21, 2022	7930356	Grant (prize money)	8562738	4935339	8598004	Scottish Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of Valneva's funding rounds and investors

Valneva's employee count trend

Valneva has 612 employees as of Sep 26. Here is Valneva's employee count trend over the years:

Uncover Valneva's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Valneva include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Valneva, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
34th	Valneva 1999, Lyon (France), Public	Developer of prophylactic vaccines for infectious diseases	$114M	Phase4 Partners, Eiffel Investment Group ... & 13 others	63/100